Myelofibrosis patients dealing with anemia often face a difficult choice between managing fatigue and maintaining disease control. New guidelines from the American Society of Hematology (ASH) aim to help doctors handle these complex decisions. The recommendations focus on anemia specifically, offering specific strategies for patients who have never used JAK inhibitors and those already on treatment.
Why Choosing the Right Doctor Matters
Rare diseases like myelofibrosis require specialized care. An estimated 60 to 75 percent of people with this condition are treated by a hematologist in their local community. However, experts say seeing a specialist in myeloproliferative neoplasms (MPN) is a standard recommendation of major organizations. These specialists stay updated on subtle research and quickly evolving treatments.
The new evidence-based guidelines were developed by an expert panel over two years. Their goal is to close gaps in decision-making and ensure consistent care. The recommendations range from expanded genetic testing to managing the prospect of a stem cell transplant, the only potential cure for myelofibrosis.
Managing Anemia After Diagnosis
For patients with anemia who have never taken a JAK inhibitor, the guidelines suggest two main paths. Doctors may prescribe JAK inhibitors that help with anemia, such as momelotinib or pacritinib. These drugs can allow some patients to stop regular blood transfusions. Pacritinib is also an option for people who have both anemia and low platelet counts.
Read Also: Gut Issues Common in Mastocytosis Patients
For patients who do not need transfusions, doctors may choose treatments aimed directly at red blood cell production. This could include an erythropoiesis-stimulating agent (ESA), an androgen, or luspatercept. This approach mirrors how doctors handle other blood disorders, where the specific cause of the low count dictates the therapy.
Patients already taking JAK inhibitors face a different set of decisions. If the current dose effectively controls the spleen and symptoms, the guidelines suggest staying on that medication. Doctors can then add anemia treatments that are not JAK inhibitors, such as transfusions or ESAs. If the drug causes anemia that prevents the patient from taking a full dose, switching therapy may be necessary.
Genetic Testing and Other Considerations
Another key recommendation involves the use of low-dose aspirin. This is specifically for patients who carry the JAK2 V617F mutation. This mutation is the most common gene change found in myelofibrosis. The guidelines suggest discussing aspirin use with the care team. Decisions about aspirin should consider the patient’s specific MF subtype. Doctors must also weigh the risk of blood clots against the risk of bleeding.
Transplant and Future Research
For lower-risk patients, the guidelines suggest avoiding JAK inhibitors. These patients do not have disease-related symptoms. Using these drugs in this group is not advised. The focus remains on monitoring the disease and managing symptoms as they arise. The recommendations cover a wide range of topics. They aim to provide a standard for hematologists treating this condition.
